Predicting Factors for Mortality in Congenital Heart Disease Patients After Shunt Procedure in Developing Country.

Blalock Taussig (BT) is a palliative procedure that preserves blood circulation to the lungs and alleviates cyanosis in patients with congenital heart diseases and reduced pulmonary blood flow. BT shunt remains a routinely performed procedure in developing countries before definitive surgery. However, evidence on predictors factors of mortality after this procedure is still scarce in Indonesia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cyanotic Congenital Heart Disease

Age range

1 day–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitas Sumatera Utara

Medan, North Sumatera, 20155, Indonesia

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All CHD pediatric patients with a previous history of BT shunt procedure.

Exclusion criteria

Pediatric patients with incomplete medical records

Treatment and study plan

Primary outcomes

In-Hospital Mortality

Time frame: November 2020 - January 2021

Death occured to patients during in hospital stay

Sponsors and collaborators

Lead sponsor

Universitas Sumatera Utara

Other

Collaborators

Indonesia University

Registry information

Official study title

Predicting Factors for Mortality in Patients After the Modified Blalock-Taussig Shunt Procedure in Developing Country: a Retrospective Study

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2021
First posted: Apr 5, 2023
Registry last updated: Aug 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed